Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $43.80 Consensus PT from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have been given a consensus rating of “Moderate Buy” by the five analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $43.80.

INO has been the topic of several research reports. HC Wainwright reaffirmed a “neutral” rating and set a $15.00 price target on shares of Inovio Pharmaceuticals in a report on Monday, July 15th. Royal Bank of Canada decreased their target price on shares of Inovio Pharmaceuticals from $8.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Friday, October 4th. Finally, Oppenheimer dropped their price target on Inovio Pharmaceuticals from $40.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday, August 12th.

Inovio Pharmaceuticals Stock Down 1.9 %

Shares of NASDAQ:INO opened at $5.56 on Wednesday. Inovio Pharmaceuticals has a 12-month low of $3.89 and a 12-month high of $14.75. The stock has a market cap of $144.07 million, a PE ratio of -1.50 and a beta of 0.82. The business has a 50 day moving average of $6.26 and a 200-day moving average of $8.67.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.09). The business had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million. During the same quarter in the previous year, the business posted ($1.56) EPS. Equities research analysts expect that Inovio Pharmaceuticals will post -4.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC purchased a new position in Inovio Pharmaceuticals during the third quarter worth about $71,000. The Manufacturers Life Insurance Company bought a new position in shares of Inovio Pharmaceuticals in the second quarter worth approximately $82,000. Signature Estate & Investment Advisors LLC purchased a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $88,000. Cornercap Investment Counsel Inc. bought a new stake in shares of Inovio Pharmaceuticals in the second quarter worth about $184,000. Finally, American Century Companies Inc. grew its position in shares of Inovio Pharmaceuticals by 62.2% in the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock worth $255,000 after buying an additional 12,100 shares during the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.